Adam Feuerstein ✡️· @adamfeuerstein · X·· 6 天前AI 评分38
AI 导读
本周Biotech Scorecard通讯： 为何吉利德 $GILD 忍不住大谈其在免疫学领域的雄心 高管们对emvistegrast尤为看好，这是一种口服alpha-4/beta-7整合素抑制剂，堪称"口服版Entyvio"。溃疡性结肠炎的II期数据预计下月读出。 https://www.statnews.com/2026/09/24/gilead-immunology-inflammation-biotech-moderna-merck/
正文
This week's Biotech Scorecard newsletter:
Why Gilead $GILD can't stop talking about its ambitions in immunology
Execs are particularly bullish about emvistegrast, an oral alpha-4/beta-7 integrin inhibitor aka Entyvio in a pill. Ph2 data in ulceratiive colitis likely reading out next month.
https://www.statnews.com/2026/09/24/gilead-immunology-inflammation-biotech-moderna-merck/
来源：Adam Feuerstein ✡️ · x.com